民生健康药业第二期股份回购进展公告详细解读
重点摘要
- 公司全称：杭州民生健康药业股份有限公司（证券代码：301507，证券简称：民生健康）
- 回购目的：用于股权激励，提升公司治理及员工积极性
- 回购进展：截至2026年4月30日，累计回购股份2,105,100股，占公司总股本0.59%
- 回购价格区间：14.22元/股至15.67元/股
- 已支付金额：31,476,595元（不含交易费用）
- 回购资金上限：5,054.40万元
- 回购价格上限：21.06元/股
- 回购计划期限：自2025年10月28日董事会通过起12个月内
- 本次回购完全符合监管及公司既定方案要求
公告详细内容及投资者须知
2026年5月8日，杭州民生健康药业股份有限公司发布了关于第二期以集中竞价交易方式回购公司股份的进展公告。公告显示，截至2026年4月30日，公司已通过回购专用证券账户，以集中竞价交易方式累计回购股份2,105,100股，占公司当前总股本的0.59%。本次回购的最高成交价为15.67元/股，最低成交价为14.22元/股，支付总金额为31,476,595元（不含交易费用）。
本次回购股份资金来源为公司自有资金，全部用于股权激励计划，这意味着公司管理层有信心通过激励计划提升员工积极性和公司治理水平，进一步推动公司业绩增长。回购价格上限为21.06元/股，回购股份数量预计在210万~240万股之间，回购总金额不超过5,054.40万元。回购计划自2025年10月28日董事会审议通过后12个月内实施。
对股东和投资者的影响（潜在价格敏感信息）
- 回购股份通常被市场视为管理层对公司未来发展的信心，有助于提升市场关注度和公司估值。
- 回购股份将直接减少市场流通股数量，可能对股价形成支撑甚至提升。
- 本次回购严格遵循了法律法规和深圳证券交易所相关规范，包括回购的时间窗口、价格限制、不得在特定时段进行回购等，保护了中小投资者利益。
- 公司重申将在回购期限内，结合市场情况继续推进回购计划，并将按照相关规定及时公告进展，投资者需关注公司持续信息披露。
其他关键事项
- 公司未在重大事项敏感期或监管规定禁止期间进行回购，确保回购行为的合规性与透明度。
- 回购操作未触及涨停价、未在无涨跌幅限制日及集合竞价时段进行，规避了市场操纵嫌疑。
- 回购完成后，股份将用于公司股权激励，有望进一步提升管理团队稳定性和公司长期价值。
结论
本次公告显示民生健康药业正稳步推进第二期股份回购，相关操作严格合规。股份回购计划不仅展现了公司管理层对未来发展的信心，也有望通过减少流通股本和提升公司治理，间接支撑公司股价。投资者应继续关注公司后续回购执行及相关信息披露，合理评估回购行为对公司长期价值的积极影响。
免责声明： 本文仅供参考，不构成任何投资建议。投资者应结合自身实际情况、风险承受能力及市场环境，谨慎决策。公司回购进展及相关信息以公司公告为准，本文不承担任何法律责任。
English Version
Detailed Analysis: Minsheng Health Pharmaceutical’s Second Share Buyback Progress
Key Points
- Company: Hangzhou Minsheng Health Pharmaceutical Co., Ltd (Stock code: 301507)
- Purpose: Share buyback for employee equity incentives, aiming to enhance corporate governance and staff motivation
- Buyback Progress: As of April 30, 2026, 2,105,100 shares repurchased, representing 0.59% of total share capital
- Repurchase Price Range: RMB 14.22 to 15.67 per share
- Total Amount Paid: RMB 31,476,595 (excluding transaction fees)
- Maximum Buyback Fund: RMB 50.544 million
- Maximum Buyback Price: RMB 21.06 per share
- Buyback Duration: Within 12 months from October 28, 2025, the date of board approval
- Compliant with all applicable rules and the company’s established buyback plan
Detailed Content & Investor Notes
On May 8, 2026, Hangzhou Minsheng Health Pharmaceutical Co., Ltd announced the progress of its second share buyback plan. As of April 30, 2026, the company had repurchased a total of 2,105,100 shares through the dedicated repurchase securities account using centralized bidding, accounting for 0.59% of the company’s total share capital. The highest repurchase price was RMB 15.67 per share, the lowest was RMB 14.22 per share, and the total amount paid was RMB 31,476,595 (excluding transaction costs).
The funds used for this buyback come from the company’s own resources and all repurchased shares are intended for equity incentive plans. This demonstrates management’s confidence in the company’s future and its commitment to improving governance and staff motivation. The maximum repurchase price is set at RMB 21.06 per share, with an estimated repurchase volume of 2.1 to 2.4 million shares, and a total buyback fund capped at RMB 50.544 million. The plan will be executed within 12 months from the board’s approval on October 28, 2025.
Shareholder and Investor Impact (Potentially Price-Sensitive Information)
- A share buyback is often viewed positively by the market as a sign of management’s confidence in the company’s future, potentially supporting or boosting the stock price.
- Reducing the number of shares in circulation can directly support the share price.
- The buyback follows all regulatory requirements and exchange guidelines, including restrictions on timing and price, protecting minority shareholder interests.
- The company will continue to disclose buyback progress in a timely manner, and investors should pay close attention to future announcements.
Other Important Points
- No repurchases occurred during sensitive periods (e.g., pending material events) or other periods prohibited by regulators, ensuring transparency and compliance.
- Buyback orders avoided price limits, auction periods, and sessions without price fluctuation limits, reducing manipulation risks.
- All repurchased shares will be used for equity incentives, which could further stabilize the management team and enhance long-term company value.
Conclusion
The ongoing share buyback reflects Minsheng Health’s solid commitment to enhancing shareholder value and corporate governance. Investors should closely monitor further progress and consider the positive potential impact of the buyback on the company’s long-term value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should assess their own risk tolerance and consult official company disclosures before making investment decisions. The author assumes no legal responsibility for any actions taken based on this article.
